ASSOCIATE DEAN DARYL LIM QUOTED ON FTC SCRUTINY OF SANOFI-BLUEPRINT MERGER
June 2025 — CTFN quoted Associate Dean for Research and Innovation Daryl Lim on June 17, 2025, regarding the antitrust review of Sanofi’s proposed acquisition of Blueprint Medicines by the Federal Trade Commission (FTC).
An expert on antitrust and innovation policy, Lim weighed in on whether Sanofi’s simultaneous control of Dupixent and Blueprint’s BLU-808 could raise competitive concerns. He explained that even if the two drugs are not direct substitutes, Sanofi’s ability to shape their development and marketing strategies could invite FTC scrutiny. “Even if they’re not direct substitutes, the ability to control how each is developed, positioned, and marketed could raise flags, especially if one could be used to block uptake of the other preemptively,” he said.
CTFN is a leading publication for financial and legal professionals, recognized for its investigative reporting on regulatory and antitrust issues pertinent to event-driven markets. Lim’s insights appeared alongside those of Rutgers Law Professor Michael Carrier, whose work has been cited by the U.S. Supreme Court. The article highlights the FTC’s interest in whether the merger could dampen future competition in treatments for chronic urticaria and related conditions.
Daryl Lim is the H. Laddie Montague Jr. Chair in Law at Penn State Dickinson Law. He is also the Associate Dean for Research and Innovation and Founding Director of the Intellectual Property (IP) Law and Innovation Initiative. At the university level, he is a co-hire at the Institute of Computational and Data Sciences and an affiliate at the Center for Socially Responsible Artificial Intelligence.
Professor Lim is an award-winning author, observer, and commentator on national and global trends in IP and competition policy and how they influence and are influenced by law, technology, economics, and politics. He helps policymakers, attorneys, corporate counsel, scholars, and the public understand the world around them. He is a founding member of the Global IP Alliance and its local chapters in Pennsylvania and Illinois. In addition, he serves as Co-Chair of the University Education Committee in the US IP Alliance.
In December 2022, the American Law Institute elected Professor Lim to its membership based on demonstrated excellence and outstanding professional achievement. In 2023, the US Department of Justice and Federal Trade Commission recognized him as “a leading expert in antitrust law and economics” and the IAM Strategy 300, a guide to the industry pioneers with “exceptional skill sets, as well as profound insights into the development, creation, and management of IP value,” named him to its World’s Leading IP Strategists 2023 list. In 2024, he was appointed to the consultative group advising the United Nations Secretary General’s High-Level Advisory Body on Artificial Intelligence. In 2025, he received the IP Professor of the Year Award at the Global Intellectual Property, Artificial Intelligence & Technology Conclave & Awards.